Explore

Streams

Products

About Index

Index

By TNW

Cormorant Capital

0

Cormorant Capital

Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing

Built with ❤︎ by Datalicious ©2020
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 3

Portfolio

Portfolio Tracker

Add info

University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO

VC-backed Cabaletta Bio begins trading on NASDAQ

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

Satsuma Pharmaceuticals goes public

BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut

BridgeBio files for $225M initial public offering

$299,200,000 Venture capital

BridgeBio Pharma racks up $299.2 mln

$50,000,000 Venture capital (Series B)

,

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup

Health Science

BridgeBio Bags $135M For “Hub and Spoke” Rare Disease Drug R&D

Health Funding

$12,000,000 Venture capital (Series A)

Satsuma Pharmaceuticals takes in $12 mln Series A